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Catheter Directed Thrombolysis in Iliofemoral Deep Vein 
Thrombosis
Fadhil P. Apriansyah1, Suko Adiarto2
Background Iliofemoral deep vein thrombosis (IFDVT) is associated 
with more severe outflow obstruction which results in more severe DVT 
symptoms and late clinical sequelae. Despite anticoagulation therapy, IFDVT 
patients is still at risk to develop postthrombotic syndrome (PTS). Recent 
studies found that additional catheter-directed thrombolytic therapy may 
offer advantages in reducing PTS and maintaining venous patency. Several 
ongoing multi-center randomized controlled trials are expected to evaluate 
safety and efficacy of CDT in IFDVT patients, and define who will benefit 
most.
Case Illustration A 59-year-old male was presented with numbness, 
pain, and movement limitation in the left leg that were preceded by left 
leg swelling. Peripheral edema was found in both patient’s leg but more 
prominent on the left side. Dupplex sonography revealed extensive soft 
thrombus from left iliac vein to left tibialis vein. Initial anticoagulation 
therapy took no effect to the thrombus. Catheter-directed thrombolysis 
was performed and provided satisfactory symptoms resolution as well as 
thrombus dissolution.
Summary A case of iliofemoral DVT has been reported. The present thera-
peutic strategy of anticoagulation therapy has not been proven to prevent 
PTS. CDT is an effective way in achieving clot lysis in acute thrombosis, 
and this may help to prevent PTS and subsequent ulceration. The potential 
benefits of therapy must be weighed carefully against the risk of bleeding. 
There are several ongoing RCTs that are awaited to help provide evidence 
on functional outcome after CDT and define who will benefit most.
(J Kardiol Indones. 2014;35:278-84)
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Latar Belakang : Trombosis vena dalam iliofemoral berhubungan dengan obstruksi aliran vena berat yang men-
gakibatkan gejala dan sekuele yang lebih berat. Pasien dengan kondisi ini memiliki risiko tinggi terjadinya sindrom 
pasca trombosis walaupun sudah mendapat terapi antikoagulan. Studi terkini menunjukkan bahwa terapi trombolisis 
dengan bantuan kateter memberikan manfaat dalam mengurangi sindrom pasca trombosis dan menjaga patensi vena. 
Beberapa randomized controlled trials besar sedang berjalan dan diharapkan dapat mengevaluasi keamanan dan efikasi 
tatalaksana ini pada pasien dengan trombosis vena dalam iliofemoral, dan juga menjelaskan siapa saja yang paling 
mendapat manfaat.
Ilustrasi Kasus : Seorang laki-laki 59 tahun datang dengan keluhan baal, nyeri, dan sulit menggerakan tungkai kiri yang dida-
hului dengan kaki bengkak. Edema perifer ditemukan pada kedua tungkai pasien namun lebih berat pada tungkai kiri. Duplex 
sonografi menunjukkan trombus yang ekstensif dari vena iliaka hingga tibialis kiri. Terapi antikoagulan saja tidak memberi 
efek terhadap trombus. Trombolisis dengan bantuan kateter dilakukan dan memberikan perbaikan gejala dan pengurangan 
trombus yang bermakna.
Kesimpulan : Dilaporkan sebuah kasus trombosis vena dalam iliofemoral. Strategi tatalaksana terkini dengan antikoagu-
lan tidak terbukti dalam hal mencegah sindrom pasca trombosis. Trombolisis dengan bantuan kateter adalah cara yang 
efektif dalam mencapai lisis bekuan darah pada trombosis akut, dan dapat membantu mencegah kejadian sindrom pasca 
trombosis. Potensi keuntungan dari terapi ini harus ditimbang baik-baik mengingat risiko perdarahan yang dapat terjadi. 
Saat ini terdapat beberapa randomized controlled trials besar yang sedang berjalan dan diharapkan dapat menyediakan 
basis bukti atas tatalaksana ini.
(J Kardiol Indones. 2014;35:278-84)
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Deep vein thrombosis (DVT) is the third most common cardiovascular pathology, after coronary artery disease and stroke. In the United Kingdom, 1 in 1000 people 
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develop DVT each year.1 However, this figure would 
likely be lower in Asian.2 Its natural history leads to 
thrombus extension, pulmonary embolism (PE), post-
thrombotic syndrome, reccurent venous thrombosis, 
and mortality after acute DVT. The primary treatment 
of DVT is systemic anticoagulation, which reduce the 
risk of PE, and the extension and recurrence of venous 
thrombosis.
Iliofemoral DVT (IFDVT) is different from other 
more distal DVT because it is associated with more 
severe outflow obstruction which results in more severe 
DVT symptoms and late clinical sequelae.3 Despite 
anticoagulation therapy, IFDVT patients is still at risk 
to develop postthrombotic syndrome (PTS) with a 
cumulative incidence of PTS of up to 50% 2 years post-
DVT.1 4 There is therefore a great need for improved 
therapy that can improve long-term functional outcome. 
Thrombolytic therapy for acute DVT is used as the 
initial treatment in order to clear the thrombus from 
the deep venous system. Recent studies found that 
additional thrombolytic therapy for rapid dissolution 
of thrombus in acute DVT may offer advantages in 
reducing PTS and maintaining venous patency. It does 
not replace anticoagulation for the treatment of these 
patients, since anticoagulation is important to prevent 
recurrence, thrombus extension and PE. Catheter-
directed thrombolysis (CDT) is the preferred tehcnique 
since systemic thrombolytic therapy is associated with 
unacceptably high risk of bleeding.
However, there has not been any strong evidence 
to support this practice. Several ongoing multi-center 
randomized controlled trials are expected to evaluate 
safety and efficacy of CDT in IFDVT patients, and 
define who will benefit most.
Case Illustration
A 59-year-old male presented to emergency depart-
ment with numbness, pain, and movement limitation 
in the left leg since six hours before admission. These 
complaints were preceded by left leg swelling since ten 
days before admission. However, there was no bluish 
discoloration. The patient had a history of dyspneu 
on exertion for the last 5 months that was worsening 
since two weeks before admission accompanied by 
orthopneu and paroxysmal nocturnal dyspneu. The 
patient had been treated at another hospital for one 
day but then return home at his own request one day 
before admission.
The patient was afebrile. Respiratory rate, blood 
pressure, and pulse were, respectively, 22 breaths/
min, 88/56 mmHg, and 93 beats/min. There was 
raised jugular vein pressure of 5+3 mmHg. The 
cardiac auscultation revealed normal first and second 
heart sound with grade 3/6 pansystolic murmur in 
the apex area.  Fine crackles were heard over the 
patient’s lung bases. Liver was palpable two fingers 
under right costal margin. Peripheral edema was 
found in both patient’s leg but more prominent on 
the left side.
His hemoglobin level was 10.8 g/dL, his white blood 
cell was 7,650 cells/mm3, and his platelet count was 
78,000 cells/mm3. The findings of blood chemistries 
level were as follow; ureum 99 mg/dL, creatini 1.32 
U/L, random blood glucose 157 mg/dL. His serum 
albumin level was 2.6 g/dL. Electrocardiography (ECG) 
examination showed sinus rythm with left QRS axis 
deviation (LAD). There was inverted T wave in V5, 
V6, I, and aVL. There was also evidence of bifasicular 
block. A chest  x-ray revealed cariothoracic ratio of 68%, 
normal aortic and pulmonary segment, and flattening 
of the cardiac waist. There was sign of right pleural ef-
fusion. However, there was no sign of congestion nor 
infiltrate.
Echocardiography examination showed decreased 
left ventricular (LV) function with ejection fraction 
(EF) of 18%, decreased right ventricular (RV) 
function with TAPSE of 0.8 cm, regional wall motion 
abnormality, moderate to severe mitral regurgitation 
(MR), and moderate tricuspid regurgitation (TR) 
with mild pulmonary hypertension. Lower extremity 
dupplex sonography was performed in this patient. 
The investigation revealed soft thrombus from left 
iliac vein to left tibialis vein (Figure 1A). In contrast, 
there was no DVT in the right leg. Arterial flow was 
normal in both legs.
Patient was then diagnosed as ADHF ec old myo-
cardial infarct, iliofemoral DVT, moderate-severe MR, 
moderate TR, mild PH, hyponatremia, hypokalemia, 
hypoalbuminemia. Initial treatment was given which 
included enoxaparin 2x60 mg SC (LWMH), furosemide 
2x20 mg IV, simvastatin 1x20 mg, captopril 3x6,25 mg. 
Dupplex sonography examination was to be evaluated 
after three days of LWMH administration to evaluate 
treatment efficacy.
 Despite LWMH treatment for three days, 
evaluation of the dupplex sonography showed 
no improvement on the DVT of the left leg. Leg 
circumference was also measured and showed 
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enlargement of the left leg compared to the right leg. 
Catheter directed thrombolysis was then planned in 
order to obtain a better result.
On the fifth day of hospitalization, the symptoms 
had not subsided yet.  CDT was prepared. CDT was 
then performed in the cathlab by an ultrasound-guided 
popliteal vein puncture approach. Venography showed 
soft thrombus from left popliteal vein to left iliac vein. 
Thrombusuction was performed in the left iliofemoral 
vein followed by alteplase administration through the 
catheter at a dose of 0,5 mg/hour. The catheter was 
left in place so the thrombolytic agent could be infused 
over the following 24 hours. LWMH was temporarily 
replaced with unfractionated heparin (UFH) at a dose 
of 100 unit/hour.
Venography evaluation was performed the follow-
ing day. Thrombus was still visible on the examina-
tion, but venous flow had improved. Administration 
of alteplase (through the sheath) and UFH were 
continued for one more day. The symptoms, how-
ever, had significantly improved and the swelling 
on the left leg had reduced. On the following day, 
alteplase and UFH were discontinued and replace 
with enoxaparin 2x60 mg SC overlapping with oral 
warfarin. Dupplex sonography evaluation showed 
partial DVT in left common femoral vein (Figure 
1B) while DVT in left external iliac vein, popliteal 
vein, and posterior tibial vein had disappeared. The 
patient was still hospitalized for the following week 
while the treatment was being optimized and the 
patient started mobilization. On the eighteenth day 
patient was discharged.
Discussion
Iliofemoral Deep Vein Thrombosis
Lower extremity DVT is typically divided into proxi-
mal DVT (highest thrombus extent in the popliteal 
vein or proximally), which carries an increased risk of 
symptomatic PE, and distal DVT (isolated calf vein 
thrombosis). However, it is suspected that proximal 
DVT patients with the most extensive thrombus bur-
den may be at higher risk for poor clinical outcomes 
than those with less extensive, but still proximal, 
DVT.3
Iliofemoral DVT refers to complete or partial 
thrombosis of any part of the iliac vein or the common 
femoral vein, with or without involvement of other 
lower extremity veins or the IVC. When the femoral 
vein is thrombosed, the primary collateral route by 
which blood leaves the extremity is by drainage into 
the deep (profunda) femoral vein (which empties 
into the common femoral vein). As a result, venous 
thrombosis above the entry point of the deep femoral 
vein (ie, thrombosis in or above the common femoral 
vein) causes more severe outflow obstruction, which 
often results in more dramatic initial DVT symptoms 
and late clinical sequelae.
In a prospective study, patients with IFDVT had a 
2.4-fold increased risk of recurrent VTE over 3 months 
of follow-up compared with patients with less extensive 
DVT.5 In a prospective, multicenter, cohort study, 
patients with DVT involving the common femoral 
vein or iliac vein had significantly increased severity 
Figure 1. A.) Femoral dupplex sonography before CDT showed thrombus in left common femoral 
artery. B.) Femoral dupplex sonography after CDT showed thrombus dissolution.
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of the postthrombotic syndrome (PTS) over 2 years 
of follow-up (P<0.001).6
IFDVT patients should receive initial anticoagu-
lant therapy for the prevention of pulmonary embolism 
(PE) and recurrent DVT. American Heart Association 
(AHA) in its 2011 Scientific Statement recommeds in-
travenous UFH (Class I; Level of Evidence A), UFH by 
subcutanous injection (Class I; Level of Evidence B), an 
LMWH (Class I; Level of Evidence A), or fondaparinux 
(Class I; Level of Evidence A) to be given to patients 
with IFDVT in the absence of suspected or proven 
heparininduced thrombocytopenia.
This patient had suffered from IFDVT with soft 
thrombus extending from left iliac vein to left tibialis vein. 
He therefore had a 2.4-fold increased risk of recurrent 
VTE over the next 3 months compared with patients 
with less extensive DVT. He also carried a significantly 
increased severity of the PTS over the next 2 years, while 
severe PTS leads to such a poor quality of life. LWMH 
which was given in this patient as an initial treatment 
was in line with AHA recommendation (Class I; Level 
of Evidence A). However, despite initial anticoagulation, 
there had not been any improvement in symptoms nor 
femoral dupplex sonography evaluation.
Postthrombotic Syndrome
PTS is a relatively common and highly significant 
sequel of DVT. Eighty percent of symptomatic DVTs 
are above the knee (proximal), with a cumulative 
incidence of PTS of up to 50% 2 years post-DVT.1,4 
Severe PTS is reported in 50% of cases, and leg 
ulceration is present in up to 10% of patients.1 These 
conditions have been a major factor impairing quality 
of life 2 years after an acute DVT.
PTS is caused by chronic venous hypertension 
secondary to venous reflux, venous obstruction, and 
valvular dysfunction. This manifests clinically as a 
heaviness, pain, edema, and venous claudication with 
skin damage. At the most severe form, PTS is associated 
with venous ulceration. Recurrent DVT is among the 
most powerful predictors and associated with an up to 
sixfold greater risk of PTS.4 Recent research has shown 
that severe PTS leads to such a poor quality of life 
that it is comparable to experiencing angina, cancer, 
or congestive heart failure.1
Catheter-directed Thrombolysis
Catheter-directed thrombolysis (CDT) refers to the 
infusion of a thrombolytic agent directly into the 
venous thrombus via a multiple–side-hole catheter 
with the use of imaging guidance. In a 473 patient 
prospective multicenter registry, the use of urokinase 
CDT resulted in successful fibrinolysis in 88% of 
patients with acute IFDVT. CDT was more often 
successful in patients with recent (≤10 to 14 days) 
onset of symptoms.3
The use of endovascular thrombolysis as an 
adjunct to anticoagulant therapy is reasonable for 
patients with acute IFDVT associated with limb-
threatening circulatory compromise, rapid thrombus 
extension despite anticoagulation, or symptomatic 
deterioration despite anticoagulation. The use of CDT 
or PCDT (along with anticoagulation) to achieve 
more rapid relief of presenting DVT symptoms 
and to prevent PTS can be considered as a first-line 
treatment in carefully selected patients with acute 
IFDVT. The potential benefits of therapy must be 
weighed carefully against the risk of bleeding since 
there are no published long-term outcome data from a 
multicenter RCT. Patient selection should be based on 
a careful assessment of the severity of DVT symptoms, 
comorbidities, life expectancy, and patient preferences 
for an aggressive treatment approach. In most IFDVT 
patients whose onset of DVT symptoms was >21 days 
before presentation or who are at high risk for bleeding 
complications, this approach should not be used (Class 
III; Level of Evidence B). 3
 Patient presented with onset of symptoms 
<21 days. Initial anticoagulation treatment had been 
given but had not shown to be effective, making CDT 
reasonable in this patient. CDT was expected to acheive 
better recanalization in thrombosed vein, and therefore 
gave a better symptoms resolution and reduced risk 
of late clinical sequelae. Despite risk of bleeding, the 
possible benefit is considered to outweigh this risk.
CDT vs Anticoagulant Alone
Despite the lack of conclusive evidence, some 
data support the argument that DVT treated with 
anticoagulation alone results in a high risk of PTS 5-10 
years later. Active removal of the thrombus with surgery 
or catheter-directed lysis clears the thrombus relatively 
quickly and improves preservation of valvular function 
while reducing the incidence and severity of PTS.
In a small (n=35) RCT, Elsharawy et al7 reported that 
streptokinase CDT plus anticoagulation yielded a higher 
rate of normal physiological venous function (72% 
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versus 12%, P<0.001) and less valvular reflux (11% 
versus 41%, P=0.04) at 6 months than anticoagulation 
alone. In an open-label multicenter RCT of 118 IFDVT 
patients, Enden et al8 found that alteplase CDT plus 
anticoagulation resulted in better 6-month iliofemoral 
vein segment patency (64% versus 36%, P=0.004), 
less functional venous obstruction (20% versus 49%, 
P=0.004), and no difference in femoropopliteal venous 
reflux (60% versus 66%, P=0.53) compared with 
anticoagulant alone. In this study, in which alteplase 
infusions of 0.01 mg . kg-1 . h-1 were used, CDT plus 
anticoagulation was associated with major bleeding in 
2.0% (major bleeding occurred in 1.7% of patients 
treated with anticoagulant alone).
In a prospective single-centre clinical series of 101 
acute IFVT patients treated with CDT, Baekgaard et 
al10 found that open veins without reflux were achieved 
in 82% of the affected lower extremities after 6 years 
without any mortality, or new PE and only a few 
cases of new DVT. For patients strictly following the 
protocol, the result was 86%.
In a meta-analysis (Figure 2) comparing efficay 
of pharmacologic CDT to systemic anticoagulation 
in acute IFDVT patients, Casey et al9 found that 
pharmacologic CDT was associated with statistically 
significant reduction in the risk of PTS (RR, 0.19; 95% 
CI, 0.07-0.48; I2 = 64%) and venous obstruction (RR, 
0.38; 95% CI, 0.18-0.37; I2 = 46%), and a trend for 
reduction in the risk of venous reflux (RR, 0.39; 95% 
CI, 0.16-1.00; I2 = 92%). On the other hand, data 
regarding patient-important outcomes such as death, 
PE, recurrence of DVT, hospitalization, and disability, 
were inconclusive.
Percutaneous Mechanical, and 
Pharmacomechanical Thrombolysis
The adjunctive use of mechanical thecniques is has 
became the standard for catheter-based management 
of extensive venous thrombosis. Percutaneous 
mechanical thrombectomy (PMT) refers to the use of 
a catheter-based device that contributes to thrombus 
removal via mechanical thrombus fragmentation or 
aspiration. There is no evidence that any device is 
effective as a stand-alone therapy for DVT, and use 
of some devices without additional thrombolytic 
agent administration may be associated with 
symptomatic PE. However, some studies suggest that 
pharmacomechanical CDT (PCDT, or the combined 
use of CDT and PMT), provides comparable clot-
removal efficacy as drug only CDT but with major 
(40% to 50%) reductions in the needed thrombolytic 
drug dose, infusion time, and hospital resource use. 
However, there are no strong prospective studies 
to validate this finding, and there may be risks 
associated with greater mechanical manipulation 
of the thrombus and vein. If PCDT fails, surgical 
thrombectomy is a valid alternative, primarily in 
acute IFDVT. No PCDT studies have systematically 
evaluated recurrent DVT and PTS.3
A B
Figure 2. Meta-analysis of pharmacologic CDT vs systemic anticoagulation.9
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Use of Other Satndard DVT Treatments in 
Patients Undergoing CDT or PCDT
Before and after CDT or PCDT, therapeutic-level 
anticoagulation should be used with similar dosing, 
treatment duration, and monitoring as for IFDVT 
patients who are not undergoing thrombolysis. During 
CDT infusions, reduced-dose UFH may be safer than 
therapeutic-level UFH. However, during single-session 
PCDT or stand-alone PMT, both of which involve 
greater mechanical manipulation, it may be reasonable 
to use therapeutic-level UFH. LMWH has also been 
used along with PCDT, but there are no studies to 
support this practice. 
Thrombosuction was performed in this patient 
followed by alteplase infusion for up to 2 days. During 
alteplase infusion, LWMH was changed with reduced-
dose UFH (100 unit/hour) to minimize the risk of 
bleeding. After finishing alteplase infusion, UFH was 
changed again to therapeutic level LWMH of 2x60 
mg and continued for several days before overlapped 
with oral anticoagulation. Despite lack of strong 
evidence regarding this practice, it had been shown 
to be effective in this patient.
Summary
A case of iliofemoral DVT has been reported. The 
present therapeutic strategy of anticoagulation therapy 
has not been proven to prevent PTS, primarily in acute 
IFDVT. CDT is an effective way in achieving clot lysis 
in acute IFDVT, and this may help to prevent PTS 
and subsequent ulceration. The potential benefits of 
therapy must be weighed carefully against the risk of 
bleeding. Several ongoing multi-center randomized 
controlled trials are expected to provide information 
about safety and efficacy of CDT in IFDVT patients, 
and define who will benefit most.
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